摘要:
Apparatuses, systems and methods are disclosed for vehicle-charged supplemental power and its concomitant energy collection, storage, and distribution. In one implementation, an apparatus is provided including a battery configured to be portable and a vehicle component including an electrical vehicle connection system to connect the battery to the alternator of a vehicle, and a control unit coupled to the electrical vehicle connection system and configured to isolate the battery from supplying charge to a vehicle system when the battery is connected to the electrical vehicle connection system, and further configured to connect or disconnect the battery to the alternator of the vehicle. In another aspect, an apparatus is provided including one or more batteries connected to a vehicle engine and configured to be charged by the engine, wherein the batteries are configured to be selectively disconnected from the vehicle engine and selectively connected to an electric wiring system.
摘要:
High clarity polypropylene articles comprising an infrared absorbing agent such as carbon black in the amount of about 0.1 to 500 parts per million by weight of polymer. Containers such as bottles can be made at substantially improved processing rates by injection stretch blow molding.
摘要:
Pharmaceutical compositions for oral administration to mammalian subjects comprise a taxane or taxane derivative (e.g., paclitaxel or docetaxel) as active ingredient and a vehicle comprising at least 30% by weight of a carrier for the taxane, said carrier having an HLB value of at least about 10. The compositions may also comprise 0–70% of a viscosity-reducing co-solubilizer. The compositions may be incorporated into conventional oral pharmaceutical dosage forms, or can be in the form of a two-part medicament wherein the first part includes the taxane in a solubilizing vehicle and the second part comprises a carrier for the taxane to promote oral absorption. Methods of treatment of taxane-responsive disease conditions employing the novel compositions are also disclosed, whereby the compositions can be administered alone or in association with an oral bioavailability enhancing agent.